Financials

News Ideas Discussions Technicals Forecast Seasonals

3320 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to CHINA RESOURCES PHARMACEUTICAL GR operating, investing, and financing activities

3320 free cash flow for H1 24 is -3.05 B HKD. For 2023, 3320 free cash flow was 12.08 B HKD and operating cash flow was 15.01 B HKD.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: HKD

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—